Tue, Sep. 6, 7:05 AM
- Danaher (NYSE:DHR) inks a deal with Cepheid (NASDAQ:CPHD) to acquire all the outstanding stock of the molecular diagnostics firm for $53 a share in cash (~$4B including debt less acquired cash). The transaction should close in Q4.
- Danaher is a conglomerate of over 20 businesses that are managed under the auspices of the Danaher Business System. Its Life Sciences & Diagnostics segment includes Beckman Coulter, HemoCure, Leica Biosystems, Leica Microsystems, Molecular Devices, Pall, Radiometer and SCIEX.
- CPHD is up 53% premarket on light volume.
Oct. 1, 2014, 5:17 PM